The prevalence of 22q11. 2DS has been estimated to be approximately 1/3000 to 1/6,000 live births. These numbers may well be higher due to the variability of the condition, difficulty in properly diagnosing, and lack of newborn screening.

One to two percent of children born with this syndrome have a life expectancy of two to three years; however, most individuals reach adulthood and can live a life span into the fifties. Early treatment should be considered for the most severe issues with this condition to prolong life expectancy.

22q11. 2 deletion syndrome can cause parathyroid glands to be smaller than usual and produce too little parathyroid hormone. This leads to hypoparathyroidism. This condition results in low levels of calcium and high levels of phosphorus in the blood.

22q Central is a 501(c)(3) non-profit organization with the goal of promoting awareness and education regarding a common, yet many times overlooked, genetic disorder known as 22q11. 2 Deletion Disorder, DiGeorge Syndrome, VCFS (velo-cardio-facial syndrome) and others.